Abeona Therapeutics, Inc. (ABEO)

Between October 21, 2024, and October 17, 2025, Abeona Therapeutics Inc.'s share price declined by 17.86%. In May 2025, institutional investors were rewarded after the stock increased by 22%. The company showed earnings on August 14, 2025. The FDA's approval of Zevaskyn® and the subsequent sale of a Priority Review Voucher (PRV) for $155 million in Q3 2025 significantly strengthened the company's financials and led to high demand for the product.

While specific detailed seasonality data for Abeona Therapeutics' products and services is limited, general seasonality signals for the stock are balanced for October, with the next statistically strong window culminating around November 15, 2025, based on 3-year averages. Historically, October has favored a short bias based on 5-year averages. Following the FDA approval and commercial launch of Zevaskyn® in Q3 2025, the company has reported high demand for this gene therapy.

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for severe, life-threatening rare diseases and oncology indications. The company's major products and pipeline candidates include Zevaskyn® for recessive dystrophic epidermolysis bullosa (RDEB), ABO-503 for X-linked Retinoschisis (XLRS), ABO-504 for Stargardt Disease, ABO-505 for Autosomal Dominant Optic Atrophy (ADOA), and AAV-based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis. Abeona utilizes its proprietary AIM capsids platform and has licensing agreements with Ultragenyx Pharmaceutical Inc. and Taysha Gene Therapies Inc.

Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio, United States, where it also operates a cGMP manufacturing facility.

Abeona Therapeutics has experienced positive developments impacting its brand reputation. In April 2025, the FDA approved Abeona's gene therapy for a rare skin disease (Zevaskyn® for RDEB). In October 2025, Abeona Therapeutics appointed James A. Gow as Senior Vice President, Head of Clinical Development & Medical Affairs. Also in October 2025, the company announced that its ABO-503 gene therapy for X-linked Retinoschisis (XLRS) was selected by the FDA for the Rare Disease Endpoint Advancement (RDEA) Pilot Program. Abeona Therapeutics and Children's Hospital Colorado announced the activation of the newest treatment center for ZEVASKYN® gene therapy in October 2025. The sale of a Priority Review Voucher (PRV) for $155 million in Q3 2025 also contributed to a strong financial position and positive outlook.

Abeona Therapeutics Inc. has a diverse ownership structure, with significant institutional and insider holdings. Institutional shareholders own approximately 68.07% of the company, insiders own 82.38%, and retail investors own 0.00% according to one source, while another indicates 61.33% institutional, 5.66% insiders, and 33.01% public/individual investors. Another report states institutional investors control 44% of the company. Major institutional owners include Nantahala Capital Management, LLC, Adage Capital Partners Gp, L.L.C., BlackRock, Inc., Suvretta Capital Management, Llc, Vanguard Group Inc., Western Standard LLC, Vivo Capital, LLC, Boone Capital Management Llc, and Geode Capital Management, Llc. Key individual owners and insiders include Sco Capital Partners LLC, Steven H. Rouhandeh, and CEO Vishwas Seshadri.